Brokerages Set Stemline Therapeutics, Inc. (STML) Price Target at $32.60

Stemline Therapeutics, Inc. (NASDAQ:STML) has earned an average recommendation of “Buy” from the nine brokerages that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $32.60.

Several research firms recently weighed in on STML. HC Wainwright reissued a “buy” rating and set a $34.00 price objective on shares of Stemline Therapeutics in a research note on Tuesday, September 12th. ValuEngine lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. BidaskClub raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, Zacks Investment Research lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th.

A number of hedge funds have recently made changes to their positions in STML. Nationwide Fund Advisors raised its holdings in Stemline Therapeutics by 7.8% during the 1st quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 858 shares during the period. Voya Investment Management LLC acquired a new stake in Stemline Therapeutics during the 2nd quarter worth approximately $102,000. Wells Fargo & Company MN raised its holdings in Stemline Therapeutics by 3.8% during the 1st quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 500 shares during the period. State of Wisconsin Investment Board acquired a new stake in Stemline Therapeutics during the 2nd quarter worth approximately $147,000. Finally, Alliancebernstein L.P. acquired a new stake in Stemline Therapeutics during the 2nd quarter worth approximately $178,000. Hedge funds and other institutional investors own 48.42% of the company’s stock.

WARNING: This article was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://ledgergazette.com/2017/10/15/brokerages-set-stemline-therapeutics-inc-stml-price-target-at-32-60.html.

Stemline Therapeutics (NASDAQ:STML) traded down 6.02% during mid-day trading on Thursday, hitting $11.70. 199,909 shares of the company were exchanged. The stock’s market cap is $274.42 million. The company has a 50 day moving average of $10.62 and a 200 day moving average of $9.07. Stemline Therapeutics has a 12-month low of $5.50 and a 12-month high of $14.60.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.18). Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%. The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.30 million. On average, equities research analysts expect that Stemline Therapeutics will post ($2.56) earnings per share for the current fiscal year.

Several research firms recently weighed in on STML. HC Wainwright reissued a “buy” rating and set a $34.00 price objective on shares of Stemline Therapeutics in a research note on Tuesday, September 12th. ValuEngine lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. BidaskClub raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, Zacks Investment Research lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th.

A number of hedge funds have recently made changes to their positions in STML. Nationwide Fund Advisors raised its holdings in Stemline Therapeutics by 7.8% during the 1st quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 858 shares during the period. Voya Investment Management LLC acquired a new stake in Stemline Therapeutics during the 2nd quarter worth approximately $102,000. Wells Fargo & Company MN raised its holdings in Stemline Therapeutics by 3.8% during the 1st quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 500 shares during the period. State of Wisconsin Investment Board acquired a new stake in Stemline Therapeutics during the 2nd quarter worth approximately $147,000. Finally, Alliancebernstein L.P. acquired a new stake in Stemline Therapeutics during the 2nd quarter worth approximately $178,000. Hedge funds and other institutional investors own 48.42% of the company’s stock.

WARNING: This article was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://ledgergazette.com/2017/10/15/brokerages-set-stemline-therapeutics-inc-stml-price-target-at-32-60.html.

Stemline Therapeutics (NASDAQ:STML) traded down 6.02% during mid-day trading on Thursday, hitting $11.70. 199,909 shares of the company were exchanged. The stock’s market cap is $274.42 million. The company has a 50 day moving average of $10.62 and a 200 day moving average of $9.07. Stemline Therapeutics has a 12-month low of $5.50 and a 12-month high of $14.60.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.18). Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%. The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.30 million. On average, equities research analysts expect that Stemline Therapeutics will post ($2.56) earnings per share for the current fiscal year.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.